A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A
- 2 June 2009
- journal article
- Published by Elsevier BV in Vaccine
- Vol. 27 (27), 3598-3604
- https://doi.org/10.1016/j.vaccine.2009.03.058
Abstract
No abstract availableThis publication has 67 references indexed in Scilit:
- Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin AVaccine, 2008
- Human Monoclonal Antibodies Directed against Toxins A and B Prevent Clostridium difficile -Induced Mortality in HamstersInfection and Immunity, 2006
- LEISHMANIA MAJOR SOLUBLE EXO-ANTIGENS (LmSEAgs) PROTECT NEONATAL BALB/C MICE FROM A SUBSEQUENT CHALLENGE WITH L. MAJOR AND STIMULATE CYTOKINE PRODUCTION BY LEISHMANIA-NAÏVE HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLSJournal of Parasitology, 2006
- Clostridium difficileToxins: Mechanism of Action and Role in DiseaseClinical Microbiology Reviews, 2005
- Active and passive immunization against Clostridium difficile diarrhea and colitisVaccine, 2004
- Clostridium difficile Vaccine and Serum Immunoglobulin G Antibody Response to Toxin AInfection and Immunity, 2003
- Electroporation improves the efficacy of DNA vaccines in large animalsVaccine, 2002
- The effect of formaldehyde, hydrogen peroxide and genetic detoxification of pertussis toxin on epitope recognition by murine monoclonal antibodiesVaccine, 1996
- Vaccination against lethalClostridium difficile enterocolitis with a nontoxic recombinant peptide of toxin ACurrent Microbiology, 1990
- Nosocomial Acquisition ofClostridium difficileInfectionThe New England Journal of Medicine, 1989